←Pregnancy

Study register · detail Fall-Kontroll-Studie (prospektiv, bevölkerungsbasiert) · Pregnancy · 2022

Peri-Pregnancy Cannabis Use and Autism Spectrum Disorder in the Offspring: Findings from the Study to Explore Early Development.

DiGuiseppi et al. ·Journal of Autism and Developmental Disorders Impact 2.2

No benefit demonstrated GRADE Low 13 citations

Samplen = 4.254 Pat.

DurationBirth cohorts 2003–2011…

ControlChildren with developmental disorders and…

EndpointASD diagnosis

Blindingn.a.

DesignFall-Kontroll-Studie (prospektiv, bevölkerungsbasiert)

Key finding

Periconceptional maternal cannabis use was not significantly associated with an increased ASD risk in the child.

Summary

Periconceptional cannabis use (3 months preconceptionally until delivery) in n=4.254 children (ASD n=1.428, DD n=1.198, POP controls n=1.628): reported usage rates 5,2 % (ASD), 3,2 % (DD), 4,4 % (POP). Adjusted odds for periconceptional cannabis use did not differ significantly between ASD cases and DD or POP controls (p>0,05) — no significantly increased ASD risk demonstrable.

PopulationChildren aged 30–68 months (birth cohorts 2003–2011) with ASD (n=1428), other developmental disorders (DD, n=1198) and population controls (POP, n=1628)

InterventionPericonceptional maternal cannabis use (3 months before conception until birth), self-reported

ControlChildren with developmental disorders (DD) and population controls (POP)

OutcomeAdjusted odds for periconceptional cannabis use did not differ significantly between ASD cases and DD or POP controls

Confidence in the evidence

Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile

Sample size ★★★★★

Blinding —

Effect size No benefit

Citations / year ★★★★★

Authors

DiGuiseppi C, Crume T, Van Dyke J, Sabourin KR, Soke GN, Croen LA, Daniels JL, Lee LC, Schieve LA, Windham GC, Friedman S, Robinson Rosenberg C.

DOI 10.1007/s10803-021-05339-4↗

Design: Fall-Kontroll-Studie (prospektiv, bevölkerungsbasiert)

Abstract

The association of autism spectrum disorder (ASD) with self-reported maternal cannabis use from 3 months pre-conception to delivery ("peri-pregnancy") was assessed in children aged 30-68 months, born 2003 to 2011. Children with ASD (N = 1428) were compared to children with other developmental delays/disorders (DD, N = 1198) and population controls (POP, N = 1628). Peri-pregnancy cannabis use was reported for 5.2% of ASD, 3.2% of DD and 4.4% of POP children. Adjusted odds of peri-pregnancy cannabis use did not differ significantly between ASD cases and DD or POP controls. Results were similar for any use during pregnancy. However, given potential risks suggested by underlying neurobiology and animal models, further studies in more recent cohorts, in which cannabis use and perception may have changed, are needed.

The impediment to action advances action. — Marcus Aurelius